Gynecology & Obstetrics (all articles) | Page 3 of 86 | Links Medicus Content Curation & Alerts in Medicine

@CircRes Alert! Compendium on Early #CVD #Pregnancy as an Early #Cardiovascular Moment: #Peripartum Cardiovascular Health https://t.co/tqOWn9AU0O

Authored by Drs. @heartdocsadiya, NA Cameron, and KJ Lindley pic.twitter.com/KlOXura8Y2

— Circulation Research (@CircRes) June 10, 2023

Podcast | Ascend your understanding of pelvic inflammatory disease

6 Jun, 2023 | 14:23h | UTC

#83: Ascend Your Understanding of Pelvic Inflammatory Disease (PID) – The Cribsiders

Brief Review | What BP target is appropriate for pregnant patients with mild chronic hypertension?

6 Jun, 2023 | 14:20h | UTC

What BP target is appropriate for pregnant patients with mild chronic hypertension? – Journal of Family Practice

Review | Patient-centered care in the management of cancer during pregnancy

6 Jun, 2023 | 14:10h | UTC

Patient-Centered Care in the Management of Cancer During Pregnancy – ASCO Educational Book

See other articles in the series: 2023 ASCO Educational Book

#ASCO23 – RCT | Simple hysterectomy shown non-inferior to radical hysterectomy in low-risk early-stage cervical cancer

5 Jun, 2023 | 13:43h | UTC

An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE). – American Society of Clinical Oncology (link to abstract – not published yet)

Commentaries:

SHAPE Trial: Radical Hysterectomy May Not Be Needed for Early-Stage, Low-Risk Cervical Cancer – ASCO Daily News

Simple Hysterectomy May Be a Safe Option for Patients With Early-Stage, Low-Risk Cervical Cancer – The ASCO Post

Review | Inflammatory lesions of the breast

2 Jun, 2023 | 12:10h | UTC

Inflammatory Lesions of the Breast – Archives of Pathology and Laboratory Medicine

M-A | Maternal alcohol consumption and the risk of miscarriage in the first and second trimesters

1 Jun, 2023 | 12:10h | UTC

Maternal alcohol consumption and the risk of miscarriage in the first and second trimesters: a systematic review and dose–response meta-analysis – Acta Obstetricia et Gynecologica Scandinavica

Cohort Study | Associations of menstrual cycle regularity and length with cardiovascular diseases

1 Jun, 2023 | 12:07h | UTC

Associations of Menstrual Cycle Regularity and Length With Cardiovascular Diseases: A Prospective Study From UK Biobank – Journal of the American Heart Association

News Release: Long or short menstrual cycles linked to higher risk of CVD including atrial fibrillation – American Heart Association

M-A | Labor induction at 39 weeks: improved outcomes but increased shoulder dystocia for nulliparous women

31 May, 2023 | 14:10h | UTC

Comparison of Maternal Labor-Related Complications and Neonatal Outcomes Following Elective Induction of Labor at 39 Weeks of Gestation vs Expectant Management: A Systematic Review and Meta-analysis – JAMA Network Open

Review | Managing menopausal symptoms, fertility, and bone health in breast cancer women on endocrine therapy

30 May, 2023 | 11:40h | UTC

Advances in the Management of Menopausal Symptoms, Fertility Preservation, and Bone Health for Women With Breast Cancer on Endocrine Therapy – ASCO Educational Book

WHO Report | Global progress in tackling maternal and newborn deaths stalls since 2015

25 May, 2023 | 11:36h | UTC

News Release: Global progress in tackling maternal and newborn deaths stalls since 2015: UN – World Health Organization

Report: Improving maternal and newborn health and survival and reducing stillbirth – Progress report 2023 – World Health Organization

A pragmatic approach to the management of menopause

25 May, 2023 | 11:30h | UTC

A pragmatic approach to the management of menopause – Canadian Medical Association Journal

News Release: Managing menopause: Hormone therapy is back – Canadian Medical Association Journal

RCT | Spironolactone enhances acne outcomes and offers a viable alternative to oral antibiotics

24 May, 2023 | 13:27h | UTC

Summary: The SAFA (Spironolactone for Adult Female Acne) trial was a multicenter, phase 3, double-blind, randomized controlled trial in England and Wales and evaluated the efficacy of spironolactone for treating adult women with acne vulgaris. A total of 410 women, aged ≥18 years and suffering from facial acne for a minimum of six months, were randomly assigned to receive either 50 mg/day of spironolactone or a placebo, increasing to 100 mg/day until week 24.

The primary outcome was measured by the Acne-Specific Quality of Life (Acne-QoL) symptom subscale score at week 12 and 24. The trial demonstrated that spironolactone improved Acne-QoL scores more effectively than the placebo, particularly at week 24. Additionally, more participants in the spironolactone group reported acne improvement, and treatment success was significantly higher in this group at week 12. Mild side effects, notably headaches, were more common in the spironolactone group.

The findings from the SAFA trial highlight spironolactone’s effectiveness, safety, and tolerability in treating adult women with acne vulgaris, suggesting it is a viable alternative to long-term antibiotic treatments. Future research is proposed on higher initial dosages of spironolactone, and its effects on different subgroups like patients with different ages, body mass index, and ethnicity.

Article: Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial – The BMJ

Editorial: What do we know about prescribing spironolactone for acne? – The BMJ

News Release: Non-antibiotic treatment for women with persistent acne shown to be effective – University of Southhampton